Artikelen met mandaten voor openbare toegang - Hans GelderblomMeer informatie
Nergens beschikbaar: 9
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ...
The Lancet 394 (10197), 478-487, 2019
Mandaten: US National Institutes of Health
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma
JG van Oosterwijk, JK Anninga, H Gelderblom, AM Cleton-Jansen, ...
Hematology/Oncology Clinics 27 (5), 1021-1048, 2013
Mandaten: KWF Kankerbestrijding
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC
N van Erp, H Gelderblom, M Van Glabbeke, A Van Oosterom, J Verweij, ...
Clinical Cancer Research 14 (24), 8308-8313, 2008
Mandaten: US National Institutes of Health
Recurrence of Ewing sarcoma: is detection by imaging follow‐up protocol associated with survival advantage?
M Heinemann, A Ranft, T Langer, H Jürgens, J Kreyer, V Vieth, ...
Pediatric blood & cancer 65 (7), e27011, 2018
Mandaten: Federal Ministry of Education and Research, Germany
Exploratory process development of pexidartinib through the tandem Tsuji–Trost reaction and Heck coupling
D Chen, Y Zhang, J Li, Y Liu
Synthesis 51 (12), 2564-2571, 2019
Mandaten: National Natural Science Foundation of China
Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high‐dose cisplatin‐based chemoradiotherapy
CML Driessen, J Leijendeckers, AD Snik, WTA van der Graaf, JP de Boer, ...
Head & neck 41 (2), 488-494, 2019
Mandaten: KWF Kankerbestrijding
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
M Apellániz-Ruiz, MH Diekstra, JM Roldán, E Boven, D Castellano, ...
Pharmacogenetics and Genomics 27 (6), 227-231, 2017
Mandaten: Government of Spain
ACTION-HD: a randomized, double-blind, placebo-controlled prospective crossover trial investigating the efficacy and safety of bupropion in Huntington's disease
H Gelderblom, W Fischer, T McLean, C Saft, R Reilmann, S Suessmuth, ...
Neurotherapeutics 10 (1), 180-181, 2013
Mandaten: German Research Foundation
SNPs and Haplotypes in DPYD and Outcome of Capecitabine–Letter
ABP van Kuilenburg, CR Largiadèr
Clinical cancer research 17 (17), 5837-5837, 2011
Mandaten: US National Institutes of Health
Ergens beschikbaar: 161
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...
The Lancet 381 (9863), 295-302, 2013
Mandaten: US National Institutes of Health
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...
The lancet oncology 15 (4), 415-423, 2014
Mandaten: Canadian Cancer Society, Cancer Research UK, National Institute for Health …
Combination chemotherapy in advanced adrenocortical carcinoma
M Fassnacht, M Terzolo, B Allolio, E Baudin, H Haak, A Berruti, S Welin, ...
New England Journal of Medicine 366 (23), 2189-2197, 2012
Mandaten: Swedish Research Council
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ...
Annals of Oncology 32 (11), 1348-1365, 2021
Mandaten: Government of Spain
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ...
Annals of Oncology 29, iv79-iv95, 2018
Mandaten: US National Institutes of Health
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ...
European journal of cancer 109, 36-50, 2019
Mandaten: US National Institutes of Health, National Fund for Scientific Research …
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label …
NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ...
The Lancet Oncology 17 (10), 1396-1408, 2016
Mandaten: US National Institutes of Health, National Fund for Scientific Research …
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good …
SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ...
Journal of Clinical Oncology 33 (20), 2279-2287, 2015
Mandaten: US National Institutes of Health, Fonds Wetenschappelijk Onderzoek …
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo) radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized …
AJ Breugom, W Van Gijn, EW Muller, Å Berglund, CBM Van den Broek, ...
Annals of Oncology 26 (4), 696-701, 2015
Mandaten: KWF Kankerbestrijding
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ...
The Lancet Oncology 19 (11), 1459-1467, 2018
Mandaten: KWF Kankerbestrijding
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials
P Rutkowski, M Van Glabbeke, CJ Rankin, W Ruka, BP Rubin, ...
Journal of clinical oncology 28 (10), 1772-1779, 2010
Mandaten: US National Institutes of Health
Publicatie- en financieringsgegevens worden automatisch vastgesteld door een computerprogramma